Spero Therapeutics Inc. Insider Trading

SPRO

Last 12 months

Insiders sold 552K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. The last open-market buy by an executive or director was in Nov 2017.

Net open-market

−552K

0 buys · 6 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 2

executives and directors

Last open-market buy

Nov 2017

Nov 6, 2017

Get an email when SPRO's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 4	Esther Rajavelu See Remarks	SoldNo plan	25,240	$2.51	63K	2.5%	Form 4
Feb 6	Esther Rajavelu See Remarks	SoldNo plan 2 parts	87,917	$2.36 average	207K	8.0%	Form 4
Feb 6	Timothy Keutzer Chief Operating Officer	SoldNo plan	18,652	$2.36	44K	2.5%	Form 4
Feb 2 – 4	Timothy Keutzer Chief Operating Officer	SoldNo plan 3 parts	46,586	$2.17 average	101K	5.8%	Form 4
Feb 2	Esther Rajavelu See Remarks	SoldNo plan	18,442	$2.20	41K	1.6%	Form 4
Nov 7, 2025	Esther Rajavelu See Remarks	SoldNo plan	40,270	$2.37	95K	4.4%	Form 4
Aug 28, 2025	Ankit Mahadevia Director	SoldNo plan	6,572	$1.97	13K	0.9%	Form 4
Aug 28, 2025	Timothy Keutzer Chief Operating Officer	SoldNo plan	1,695	$1.97	3K	0.2%	Form 4
Feb 5, 2025	Timothy Keutzer Chief Operating Officer	SoldNo plan 3 parts	56,537	$0.78 average	44K	7.1%	Form 4
Feb 5, 2025	Esther Rajavelu CFO & Cbo	SoldNo plan	20,689	$0.78	16K	2.8%	Form 4
Feb 5, 2025	Sath Shukla CEO & President	SoldNo plan 3 parts	155,333	$0.78 average	121K	8.2%	Form 4
Feb 5, 2025	Ankit Mahadevia Director	SoldNo plan 2 parts	69,219	$0.78 average	54K	9.1%	Form 4
Nov 7, 2024 – Nov 8, 2024	Esther Rajavelu CFO & Cbo	SoldNo plan 2 parts	40,596	$1.31 average	53K	9.7%	Form 4

May 4No plan
Esther Rajavelu
See Remarks · sold 25,240 at $2.51
63K
2.5% of stake
Feb 6No plan
Esther Rajavelu
See Remarks · sold 87,917 at avg $2.36
207K
8.0% of stake
Feb 6No plan
Timothy Keutzer
Chief Operating Officer · sold 18,652 at $2.36
44K
2.5% of stake
Feb 2 – 4No plan
Timothy Keutzer
Chief Operating Officer · sold 46,586 at avg $2.17
101K
5.8% of stake
Feb 2No plan
Esther Rajavelu
See Remarks · sold 18,442 at $2.20
41K
1.6% of stake
Nov 7, 2025No plan
Esther Rajavelu
See Remarks · sold 40,270 at $2.37
95K
4.4% of stake
Aug 28, 2025No plan
Ankit Mahadevia
Director · sold 6,572 at $1.97
13K
0.9% of stake
Aug 28, 2025No plan
Timothy Keutzer
Chief Operating Officer · sold 1,695 at $1.97
3K
0.2% of stake
Feb 5, 2025No plan
Timothy Keutzer
Chief Operating Officer · sold 56,537 at avg $0.78
44K
7.1% of stake
Feb 5, 2025No plan
Esther Rajavelu
CFO & Cbo · sold 20,689 at $0.78
16K
2.8% of stake
Feb 5, 2025No plan
Sath Shukla
CEO & President · sold 155,333 at avg $0.78
121K
8.2% of stake
Feb 5, 2025No plan
Ankit Mahadevia
Director · sold 69,219 at avg $0.78
54K
9.1% of stake
Nov 7, 2024 – Nov 8, 2024No plan
Esther Rajavelu
CFO & Cbo · sold 40,596 at avg $1.31
53K
9.7% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SPRO, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SPRO

CompareIntrinsic value

INBPIntegrated BioPharma Inc.

$0.17+2.21%28

XOMAXOMA Corporation

€0.05-3.60%64

BFRIBiofrontera Inc.

$0.90+1.55%30

WVEWave Life Sciences Ltd.

$3.62+1.12%40

CRNXCrinetics Pharmaceuticals Inc.

No recent price40

OCULOcular Therapeutix Inc.

$7.14+4.69%10

CARMCarisma Therapeutics Inc.

$0.00+100.00%60

CELUCelularity Inc.

$0.81-1.00%0

Held by ETFs

SPRO is in 1 US ETF. The largest of them, with SPRO's weight in each:

Invesco NASDAQ Future Gen 200 ETFQQQS0.53%of the fund

Spot a number that looks wrong? Check it in SPRO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SPRO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.